CLLS 6-K SEC Filing Analysis

Latest settled — T+5d

CLLS ▼ -7.50% at T+5d

NEUTRAL call ✗ call lost -7.50% · α vs SPY -9.19% · entry $4.00 → $3.70

Next anchor: T+20d in 5d

Currently $3.63 · -9.25% from $4.00 entry

Entry anchored
Apr 27, 03:48 PM ET
via Databento tick

T+1d

-5.70%

call -5.70% · α -5.69%

$3.77

settled 23d ago

T+5d

-7.50%

call -7.50% · α -9.19%

$3.70

settled 17d ago

T+20d

—

call — · α —

—

in 5d

T+60d

—

call — · α —

—

in 2mo

Price Chart

Loading chart...

Executive Summary

Cellectis announced preclinical data on its TALE-based epigenetic editing platform (TALEM) at the ASGCT annual meeting, achieving >90% sustained gene knockdown in two targets without DNA breaks. This is an early-stage research update with no immediate financial or regulatory implications.

Actionable Insight

Routine scientific conference presentation with no material financial impact. Monitor for potential partnership or clinical advancement of the epigenetic platform, but no immediate trading catalyst.

Key Facts

TALEM epigenetic editors achieved >90% reduction in gene activity in hepatocytes and T-cells
No DNA breaks or sequence modifications required
Poster presentation at ASGCT on May 13, 2026
Preclinical data; not yet in clinical trials for this platform

Financial Impact

No financial data provided in this filing

Risk Factors

Epigenetic editing remains early-stage with no clinical validation
Cellectis primarily focused on CAR-T therapies; this platform may not advance

Market Snapshot

Exchange

Nasdaq

Sector

Biological Products, (No Diagnostic Substances)

Analyst Consensus

85% bullish (13 analysts)

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

Document	Accession Number
6-K Filing (Primary)	0001171843-26-002734
Document: f6k_042726.htm	0001171843-26-002734
Document: 0001171843-26-002734-index-headers.html	0001171843-26-002734
Document: 0001171843-26-002734-index.html	0001171843-26-002734
Document: 0001171843-26-002734.txt	0001171843-26-002734

6 reports for CLLS

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for CLLS — sortable, filterable
	Type				Now
May 12, 2026 9d ago	6-K NEUTRAL ★ 3/10	$3.96 $3.85	▼ −2.78%	▼ −2.86%	$3.63 (−8.33%)
May 4, 2026 16d ago	6-K NEUTRAL ★ 2/10	$3.76 $3.96	▲ +5.32%	▲ +3.33%	$3.63 (−3.46%)
Apr 27, 2026 23d ago	6-K NEUTRAL ★ 2/10	$4.00 $3.70	▼ −7.50%	▼ −9.19%	$3.63 (−9.25%)
Apr 13, 2026 5w ago	6-K BULLISH ★ 7/10	$4.16 $4.00	▼ −3.85%	▼ −5.24%	$3.63 (−12.74%)
Apr 13, 2026 5w ago	Press Release BULLISH ★ 8/10	$4.16 $4.00	▼ −3.85%	▼ −5.24%	$3.63 (−12.74%)
Mar 30, 2026 7w ago	Court Ruling NEUTRAL ★ 3/10	$3.10 $3.36	▲ +8.39%	▲ +4.09%	$3.63 (+17.10%)

US Market Status

Market Open — Closes in 4h 38m

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access